264.TEMPLES OF INDIA DATASET ANALYSIS USING PROC PRINT | PROC CONTENTS | PROC SORT | PROC FREQ | PROC MEANS | PROC SQL | PROC TABULATE | PROC REPORT | PROC TRANSPOSE | PROC FORMAT | PROC RANK | PROC SGPLOT | MACROS

on
0

139.ADVANCED CLINICAL TRIALS ANALYSIS USING SAS

on

    ADVANCED CLINICAL TRIALS ANALYSIS USING SAS


/* Creating a Comprehensive Clinical Trials Dataset */

DATA Clinical_Trials;

    LENGTH Drug_Name $20 Trial_Phase $10 Gender $6 Age_Group $10 Adverse_Effects $30 Dosage_mg 8;

    INPUT Drug_ID Drug_Name $ Trial_Phase $ Gender $ Age_Group $ Efficacy_Percentage Adverse_Effects $ Dosage_mg;

    DATALINES;

    101 DrugA Phase1 Male 18-25 78 Nausea 50

    102 DrugA Phase1 Female 26-35 82 Headache 55

    103 DrugA Phase2 Male 36-45 85 None 60

    104 DrugB Phase1 Female 18-25 60 Dizziness 45

    105 DrugB Phase3 Male 26-35 92 None 70

    106 DrugC Phase2 Female 36-45 74 Fatigue 65

    107 DrugC Phase3 Male 46-60 88 Nausea 80

    108 DrugD Phase1 Female 18-25 55 Rash 40

    109 DrugD Phase2 Male 26-35 80 None 75

    110 DrugE Phase3 Female 36-45 90 Vomiting 85

    111 DrugF Phase1 Male 46-60 65 Headache 50

    112 DrugG Phase2 Female 18-25 70 Fatigue 55

    113 DrugH Phase3 Male 26-35 95 None 90

    114 DrugI Phase1 Female 36-45 58 Rash 42

    115 DrugJ Phase2 Male 46-60 82 Dizziness 78

    116 DrugK Phase3 Female 18-25 89 None 88

    117 DrugL Phase1 Male 26-35 72 Fatigue 60

    118 DrugM Phase2 Female 36-45 77 Dizziness 62

    119 DrugN Phase3 Male 46-60 85 Headache 80

    120 DrugO Phase1 Female 18-25 68 Rash 58

    121 DrugP Phase2 Male 26-35 91 Nausea 77

    122 DrugQ Phase1 Female 36-45 75 Headache 64

    123 DrugR Phase2 Male 46-60 83 None 82

    124 DrugS Phase3 Female 18-25 88 Dizziness 79

    125 DrugT Phase1 Male 26-35 79 Rash 66

    126 DrugU Phase2 Female 36-45 81 None 70

    127 DrugV Phase3 Male 46-60 87 Fatigue 85

    128 DrugW Phase1 Female 18-25 64 Vomiting 50

    129 DrugX Phase2 Male 26-35 90 None 92

    130 DrugY Phase3 Female 36-45 93 Headache 94

    131 DrugZ Phase1 Male 46-60 62 Rash 48

    132 DrugAA Phase2 Female 18-25 80 Nausea 75

    ;

RUN;

/* Viewing the first few records */

PROC PRINT DATA=Clinical_Trials (OBS=30);

RUN;


OUTPUT:

Obs Drug_Name Trial_Phase Gender Age_Group Adverse_Effects Dosage_mg Drug_ID Efficacy_Percentage
1 DrugA Phase1 Male 18-25 Nausea 50 101 78
2 DrugA Phase1 Female 26-35 Headache 55 102 82
3 DrugA Phase2 Male 36-45 None 60 103 85
4 DrugB Phase1 Female 18-25 Dizziness 45 104 60
5 DrugB Phase3 Male 26-35 None 70 105 92
6 DrugC Phase2 Female 36-45 Fatigue 65 106 74
7 DrugC Phase3 Male 46-60 Nausea 80 107 88
8 DrugD Phase1 Female 18-25 Rash 40 108 55
9 DrugD Phase2 Male 26-35 None 75 109 80
10 DrugE Phase3 Female 36-45 Vomiting 85 110 90
11 DrugF Phase1 Male 46-60 Headache 50 111 65
12 DrugG Phase2 Female 18-25 Fatigue 55 112 70
13 DrugH Phase3 Male 26-35 None 90 113 95
14 DrugI Phase1 Female 36-45 Rash 42 114 58
15 DrugJ Phase2 Male 46-60 Dizziness 78 115 82
16 DrugK Phase3 Female 18-25 None 88 116 89
17 DrugL Phase1 Male 26-35 Fatigue 60 117 72
18 DrugM Phase2 Female 36-45 Dizziness 62 118 77
19 DrugN Phase3 Male 46-60 Headache 80 119 85
20 DrugO Phase1 Female 18-25 Rash 58 120 68
21 DrugP Phase2 Male 26-35 Nausea 77 121 91
22 DrugQ Phase1 Female 36-45 Headache 64 122 75
23 DrugR Phase2 Male 46-60 None 82 123 83
24 DrugS Phase3 Female 18-25 Dizziness 79 124 88
25 DrugT Phase1 Male 26-35 Rash 66 125 79
26 DrugU Phase2 Female 36-45 None 70 126 81
27 DrugV Phase3 Male 46-60 Fatigue 85 127 87
28 DrugW Phase1 Female 18-25 Vomiting 50 128 64
29 DrugX Phase2 Male 26-35 None 92 129 90
30 DrugY Phase3 Female 36-45 Headache 94 130 93


/* Descriptive Statistics */

PROC MEANS DATA=Clinical_Trials MEAN MEDIAN MIN MAX STD VAR;

    VAR Efficacy_Percentage Dosage_mg;

RUN;


OUTPUT:

                                                                                The MEANS Procedure

Variable Mean Median Minimum Maximum Std Dev Variance
Efficacy_Percentage
Dosage_mg
78.6875000
67.8125000
80.5000000
68.0000000
55.0000000
40.0000000
95.0000000
94.0000000
11.1106967
15.6544078
123.4475806
245.0604839


/* Analyzing Adverse Effects Frequency */

PROC FREQ DATA=Clinical_Trials;

    TABLES Adverse_Effects / CHISQ;

RUN;


OUTPUT:

                                                                       The FREQ Procedure

Adverse_Effects Frequency Percent Cumulative
Frequency		 Cumulative
Percent
Dizziness 4 12.50 4 12.50
Fatigue 4 12.50 8 25.00
Headache 5 15.63 13 40.63
Nausea 4 12.50 17 53.13
None 8 25.00 25 78.13
Rash 5 15.63 30 93.75
Vomiting 2 6.25 32 100.00


Chi-Square Test
for Equal Proportions
Chi-Square 4.3125
DF 6
Pr > ChiSq 0.6345
WARNING: The table cells have expected counts less
than 5. Chi-Square may not be a valid test.


/* Distribution of Efficacy Scores */

PROC UNIVARIATE DATA=Clinical_Trials;

    VAR Efficacy_Percentage Dosage_mg;

    HISTOGRAM Efficacy_Percentage / NORMAL;

RUN;


OUTPUT:

                                                          The UNIVARIATE Procedure
                                           Fitted Normal Distribution for Efficacy_Percentage

Parameters for Normal Distribution
Parameter Symbol Estimate
Mean Mu 78.6875
Std Dev Sigma 11.1107

                                                           The UNIVARIATE Procedure
                                                                Variable: Dosage_mg

Moments
N 32 Sum Weights 32
Mean 67.8125 Sum Observations 2170
Std Deviation 15.6544078 Variance 245.060484
Skewness -0.0880293 Kurtosis -1.1228854
Uncorrected SS 154750 Corrected SS 7596.875
Coeff Variation 23.084841 Std Error Mean 2.76733448


/* Boxplot for Efficacy by Trial Phase */

PROC SGPLOT DATA=Clinical_Trials;

    VBOX Efficacy_Percentage / CATEGORY=Trial_Phase;

    TITLE 'Efficacy by Trial Phase';

RUN;


/* Linear Regression Analysis */

PROC REG DATA=Clinical_Trials;

    MODEL Efficacy_Percentage = Drug_ID Dosage_mg;

RUN;


/* ANOVA for Different Phases */

PROC GLM DATA=Clinical_Trials;

    CLASS Trial_Phase;

    MODEL Efficacy_Percentage = Trial_Phase Dosage_mg;

    MEANS Trial_Phase / TUKEY;

RUN;


OUTPUT:

                                                              The GLM Procedure
 
                              Tukey's Studentized Range (HSD) Test for Efficacy_Percentage

Note: This test controls the Type I experimentwise error rate.

Alpha 0.05
Error Degrees of Freedom 28
Error Mean Square 26.74439
Critical Value of Studentized Range 3.49918


Comparisons significant at the 0.05 level are indicated by ***.
Trial_Phase
Comparison		 Difference
Between
Means		 Simultaneous 95% Confidence
Limits		  
Phase3 - Phase2 8.485 2.734 14.236 ***
Phase3 - Phase1 21.500 15.858 27.142 ***
Phase2 - Phase3 -8.485 -14.236 -2.734 ***
Phase2 - Phase1 13.015 7.674 18.356 ***
Phase1 - Phase3 -21.500 -27.142 -15.858 ***
Phase1 - Phase2 -13.015 -18.356 -7.674 ***


/* Correlation Between Drug ID, Dosage, and Efficacy */

PROC CORR DATA=Clinical_Trials PEARSON SPEARMAN;

    VAR Drug_ID Dosage_mg Efficacy_Percentage;

RUN;


OUTPUT:

                                                            The CORR Procedure

3 Variables: Drug_ID Dosage_mg Efficacy_Percentage


Simple Statistics
Variable N Mean Std Dev Median Minimum Maximum
Drug_ID 32 116.50000 9.38083 116.50000 101.00000 132.00000
Dosage_mg 32 67.81250 15.65441 68.00000 40.00000 94.00000
Efficacy_Percentage 32 78.68750 11.11070 80.50000 55.00000 95.00000


Pearson Correlation Coefficients, N = 32
Prob > |r| under H0: Rho=0
  Drug_ID Dosage_mg Efficacy_Percentage
Drug_ID
1.00000
 
0.34487
0.0532
0.09192
0.6168
Dosage_mg
0.34487
0.0532
1.00000
 
0.88877
<.0001
Efficacy_Percentage
0.09192
0.6168
0.88877
<.0001
1.00000
 


Spearman Correlation Coefficients, N = 32
Prob > |r| under H0: Rho=0
  Drug_ID Dosage_mg Efficacy_Percentage
Drug_ID
1.00000
 
0.33443
0.0614
0.08618
0.6391
Dosage_mg
0.33443
0.0614
1.00000
 
0.87832
<.0001
Efficacy_Percentage
0.08618
0.6391
0.87832
<.0001
1.00000
 


/* Data Normalization */

DATA Clinical_Trials_Normalized;

    SET Clinical_Trials;

    Normalized_Efficacy = (Efficacy_Percentage - 60) / (95 - 60);

    Normalized_Dosage = (Dosage_mg - 40) / (95 - 40);

RUN;

PROC PRINT DATA=Clinical_Trials_Normalized;

RUN;


OUTPUT:

Obs Drug_Name Trial_Phase Gender Age_Group Adverse_Effects Dosage_mg Drug_ID Efficacy_Percentage Normalized_Efficacy Normalized_Dosage
1 DrugA Phase1 Male 18-25 Nausea 50 101 78 0.51429 0.18182
2 DrugA Phase1 Female 26-35 Headache 55 102 82 0.62857 0.27273
3 DrugA Phase2 Male 36-45 None 60 103 85 0.71429 0.36364
4 DrugB Phase1 Female 18-25 Dizziness 45 104 60 0.00000 0.09091
5 DrugB Phase3 Male 26-35 None 70 105 92 0.91429 0.54545
6 DrugC Phase2 Female 36-45 Fatigue 65 106 74 0.40000 0.45455
7 DrugC Phase3 Male 46-60 Nausea 80 107 88 0.80000 0.72727
8 DrugD Phase1 Female 18-25 Rash 40 108 55 -0.14286 0.00000
9 DrugD Phase2 Male 26-35 None 75 109 80 0.57143 0.63636
10 DrugE Phase3 Female 36-45 Vomiting 85 110 90 0.85714 0.81818
11 DrugF Phase1 Male 46-60 Headache 50 111 65 0.14286 0.18182
12 DrugG Phase2 Female 18-25 Fatigue 55 112 70 0.28571 0.27273
13 DrugH Phase3 Male 26-35 None 90 113 95 1.00000 0.90909
14 DrugI Phase1 Female 36-45 Rash 42 114 58 -0.05714 0.03636
15 DrugJ Phase2 Male 46-60 Dizziness 78 115 82 0.62857 0.69091
16 DrugK Phase3 Female 18-25 None 88 116 89 0.82857 0.87273
17 DrugL Phase1 Male 26-35 Fatigue 60 117 72 0.34286 0.36364
18 DrugM Phase2 Female 36-45 Dizziness 62 118 77 0.48571 0.40000
19 DrugN Phase3 Male 46-60 Headache 80 119 85 0.71429 0.72727
20 DrugO Phase1 Female 18-25 Rash 58 120 68 0.22857 0.32727
21 DrugP Phase2 Male 26-35 Nausea 77 121 91 0.88571 0.67273
22 DrugQ Phase1 Female 36-45 Headache 64 122 75 0.42857 0.43636
23 DrugR Phase2 Male 46-60 None 82 123 83 0.65714 0.76364
24 DrugS Phase3 Female 18-25 Dizziness 79 124 88 0.80000 0.70909
25 DrugT Phase1 Male 26-35 Rash 66 125 79 0.54286 0.47273
26 DrugU Phase2 Female 36-45 None 70 126 81 0.60000 0.54545
27 DrugV Phase3 Male 46-60 Fatigue 85 127 87 0.77143 0.81818
28 DrugW Phase1 Female 18-25 Vomiting 50 128 64 0.11429 0.18182
29 DrugX Phase2 Male 26-35 None 92 129 90 0.85714 0.94545
30 DrugY Phase3 Female 36-45 Headache 94 130 93 0.94286 0.98182
31 DrugZ Phase1 Male 46-60 Rash 48 131 62 0.05714 0.14545
32 DrugAA Phase2 Female 18-25 Nausea 75 132 80 0.57143 0.63636


/* Logistic Regression to Predict Adverse Effects */

PROC LOGISTIC DATA=Clinical_Trials;

    CLASS Gender Trial_Phase Age_Group / PARAM=REF;

    MODEL Adverse_Effects = Gender Trial_Phase Age_Group Efficacy_Percentage Dosage_mg / LINK=GLOGIT SELECTION=FORWARD;

RUN;


OUTPUT:

                                                       The LOGISTIC Procedure

Model Information
Data Set WORK.CLINICAL_TRIALS
Response Variable Adverse_Effects
Number of Response Levels 7
Model generalized logit
Optimization Technique Newton-Raphson


Number of Observations Read 32
Number of Observations Used 32

/* Exporting Final Dataset */

PROC EXPORT DATA=Clinical_Trials

    OUTFILE='clinical_trials_extended.csv'

    DBMS=CSV

    REPLACE;

RUN;


/* Extended Analysis on Gender Influence */

PROC TTEST DATA=Clinical_Trials;

    CLASS Gender;

    VAR Efficacy_Percentage Dosage_mg;

RUN;


OUTPUT:

                                                        The TTEST Procedure
 
                                                   Variable: Efficacy_Percentage

Gender N Mean Std Dev Std Err Minimum Maximum
Female 16 75.2500 11.9359 2.9840 55.0000 93.0000
Male 16 82.1250 9.3515 2.3379 62.0000 95.0000
Diff (1-2)   -6.8750 10.7219 3.7908    


Gender Method Mean 95% CL Mean Std Dev 95% CL Std Dev
Female   75.2500 68.8898 81.6102 11.9359 8.8171 18.4731
Male   82.1250 77.1420 87.1080 9.3515 6.9080 14.4732
Diff (1-2) Pooled -6.8750 -14.6167 0.8667 10.7219 8.5680 14.3316
Diff (1-2) Satterthwaite -6.8750 -14.6354 0.8854    


Variable: Dosage_mg

Gender N Mean Std Dev Std Err Minimum Maximum
Female 16 64.1875 16.5699 4.1425 40.0000 94.0000
Male 16 71.4375 14.2780 3.5695 48.0000 92.0000
Diff (1-2)   -7.2500 15.4665 5.4682    

Gender Method Mean 95% CL Mean Std Dev 95% CL Std Dev
Female   64.1875 55.3580 73.0170 16.5699 12.2403 25.6451
Male   71.4375 63.8293 79.0457 14.2780 10.5473 22.0980
Diff (1-2) Pooled -7.2500 -18.4176 3.9176 15.4665 12.3595 20.6737
Diff (1-2) Satterthwaite -7.2500 -18.4279 3.9279    


/* Creating a New Subset with High Efficacy Drugs */

DATA High_Efficacy_Drugs;

    SET Clinical_Trials;

    IF Efficacy_Percentage > 85;

RUN;

PROC PRINT DATA=High_Efficacy_Drugs;

RUN;


OUTPUT:

Obs Drug_Name Trial_Phase Gender Age_Group Adverse_Effects Dosage_mg Drug_ID Efficacy_Percentage
1 DrugB Phase3 Male 26-35 None 70 105 92
2 DrugC Phase3 Male 46-60 Nausea 80 107 88
3 DrugE Phase3 Female 36-45 Vomiting 85 110 90
4 DrugH Phase3 Male 26-35 None 90 113 95
5 DrugK Phase3 Female 18-25 None 88 116 89
6 DrugP Phase2 Male 26-35 Nausea 77 121 91
7 DrugS Phase3 Female 18-25 Dizziness 79 124 88
8 DrugV Phase3 Male 46-60 Fatigue 85 127 87
9 DrugX Phase2 Male 26-35 None 92 129 90
10 DrugY Phase3 Female 36-45 Headache 94 130 93


/* Clustering Analysis for Trial Phases */

PROC FASTCLUS DATA=Clinical_Trials OUT=Clustered MAXCLUSTERS=3;

    VAR Efficacy_Percentage Dosage_mg;

RUN;

PROC PRINT DATA=Clustered;

RUN;


OUTPUT:

Obs Drug_Name Trial_Phase Gender Age_Group Adverse_Effects Dosage_mg Drug_ID Efficacy_Percentage CLUSTER DISTANCE
1 DrugA Phase1 Male 18-25 Nausea 50 101 78 1 14.2039
2 DrugA Phase1 Female 26-35 Headache 55 102 82 1 9.9038
3 DrugA Phase2 Male 36-45 None 60 103 85 1 7.8794
4 DrugB Phase1 Female 18-25 Dizziness 45 104 60 2 1.0672
5 DrugB Phase3 Male 26-35 None 70 105 92 1 14.8465
6 DrugC Phase2 Female 36-45 Fatigue 65 106 74 1 4.4066
7 DrugC Phase3 Male 46-60 Nausea 80 107 88 3 4.8319
8 DrugD Phase1 Female 18-25 Rash 40 108 55 2 8.1326
9 DrugD Phase2 Male 26-35 None 75 109 80 1 10.9278
10 DrugE Phase3 Female 36-45 Vomiting 85 110 90 3 1.0365
11 DrugF Phase1 Male 46-60 Headache 50 111 65 2 6.0116
12 DrugG Phase2 Female 18-25 Fatigue 55 112 70 1 12.4131
13 DrugH Phase3 Male 26-35 None 90 113 95 3 7.9876
14 DrugI Phase1 Female 36-45 Rash 42 114 58 2 4.6696
15 DrugJ Phase2 Male 46-60 Dizziness 78 115 82 3 9.7086
16 DrugK Phase3 Female 18-25 None 88 116 89 3 3.2727
17 DrugL Phase1 Male 26-35 Fatigue 60 117 72 1 7.5994
18 DrugM Phase2 Female 36-45 Dizziness 62 118 77 1 2.5725
19 DrugN Phase3 Male 46-60 Headache 80 119 85 3 6.1925
20 DrugO Phase1 Female 18-25 Rash 58 120 68 1 12.0506
21 DrugP Phase2 Male 26-35 Nausea 77 121 91 3 7.9819
22 DrugQ Phase1 Female 36-45 Headache 64 122 75 1 3.3393
23 DrugR Phase2 Male 46-60 None 82 123 83 3 6.5908
24 DrugS Phase3 Female 18-25 Dizziness 79 124 88 3 5.8139
25 DrugT Phase1 Male 26-35 Rash 66 125 79 1 1.9195
26 DrugU Phase2 Female 36-45 None 70 126 81 1 6.3837
27 DrugV Phase3 Male 46-60 Fatigue 85 127 87 3 2.0185
28 DrugW Phase1 Female 18-25 Vomiting 50 128 64 2 5.3359
29 DrugX Phase2 Male 26-35 None 92 129 90 3 7.3412
30 DrugY Phase3 Female 36-45 Headache 94 130 93 3 10.0987
31 DrugZ Phase1 Male 46-60 Rash 48 131 62 2 2.5441
32 DrugAA Phase2 Female 18-25 Nausea 75 132 80 1 10.9278


/* Additional Analysis: Comparing Efficacy across Age Groups */

PROC GLM DATA=Clinical_Trials;

    CLASS Age_Group;

    MODEL Efficacy_Percentage = Age_Group Dosage_mg;

    MEANS Age_Group / TUKEY;

RUN;


OUTPUT:

                                                        The GLM Procedure
 
                                 Tukey's Studentized Range (HSD) Test for Efficacy_Percentage

Note: This test controls the Type I experimentwise error rate.

Alpha 0.05
Error Degrees of Freedom 27
Error Mean Square 24.70637
Critical Value of Studentized Range 3.87009


Comparisons significant at the 0.05 level are indicated by ***.
Age_Group
Comparison		 Difference
Between
Means		 Simultaneous 95% Confidence
Limits		  
26-35 - 36-45 6.000 -0.801 12.801  
26-35 - 46-60 6.268 -0.772 13.308  
26-35 - 18-25 12.681 6.071 19.290 ***
36-45 - 26-35 -6.000 -12.801 0.801  
36-45 - 46-60 0.268 -6.772 7.308  
36-45 - 18-25 6.681 0.071 13.290 ***
46-60 - 26-35 -6.268 -13.308 0.772  
46-60 - 36-45 -0.268 -7.308 6.772  
46-60 - 18-25 6.413 -0.442 13.268  
18-25 - 26-35 -12.681 -19.290 -6.071 ***
18-25 - 36-45 -6.681 -13.290 -0.071 ***
18-25 - 46-60 -6.413 -13.268 0.442  


/* Extending Dataset with More Records */

DATA Clinical_Trials_Extended;

    SET Clinical_Trials;

    OUTPUT;

    Drug_ID = Drug_ID + 100;

    Efficacy_Percentage = Efficacy_Percentage - 5 + RANUNI(12345)*10;

    Dosage_mg = Dosage_mg + 5 - RANUNI(12345)*10;

    OUTPUT;

RUN;

PROC PRINT DATA=Clinical_Trials_Extended (OBS=40);

RUN;


OUTPUT:
Obs Drug_Name Trial_Phase Gender Age_Group Adverse_Effects Dosage_mg Drug_ID Efficacy_Percentage
1 DrugA Phase1 Male 18-25 Nausea 50.0000 101 78.0000
2 DrugA Phase1 Male 18-25 Nausea 47.5481 201 76.6292
3 DrugA Phase1 Female 26-35 Headache 55.0000 102 82.0000
4 DrugA Phase1 Female 26-35 Headache 57.2372 202 85.3106
5 DrugA Phase2 Male 36-45 None 60.0000 103 85.0000
6 DrugA Phase2 Male 36-45 None 57.7112 203 81.8382
7 DrugB Phase1 Female 18-25 Dizziness 45.0000 104 60.0000
8 DrugB Phase1 Female 18-25 Dizziness 42.6568 204 55.7789
9 DrugB Phase3 Male 26-35 None 70.0000 105 92.0000
10 DrugB Phase3 Male 26-35 None 67.3592 205 94.0725
11 DrugC Phase2 Female 36-45 Fatigue 65.0000 106 74.0000
12 DrugC Phase2 Female 36-45 Fatigue 68.1841 206 73.8775
13 DrugC Phase3 Male 46-60 Nausea 80.0000 107 88.0000
14 DrugC Phase3 Male 46-60 Nausea 81.0640 207 84.5277
15 DrugD Phase1 Female 18-25 Rash 40.0000 108 55.0000
16 DrugD Phase1 Female 18-25 Rash 36.4051 208 54.5952
17 DrugD Phase2 Male 26-35 None 75.0000 109 80.0000
18 DrugD Phase2 Male 26-35 None 78.1871 209 78.9254
19 DrugE Phase3 Female 36-45 Vomiting 85.0000 110 90.0000
20 DrugE Phase3 Female 36-45 Vomiting 87.6468 210 86.6223
21 DrugF Phase1 Male 46-60 Headache 50.0000 111 65.0000
22 DrugF Phase1 Male 46-60 Headache 49.3007 211 62.8021
23 DrugG Phase2 Female 18-25 Fatigue 55.0000 112 70.0000
24 DrugG Phase2 Female 18-25 Fatigue 51.9984 212 68.5052
25 DrugH Phase3 Male 26-35 None 90.0000 113 95.0000
26 DrugH Phase3 Male 26-35 None 91.3577 213 96.1897
27 DrugI Phase1 Female 36-45 Rash 42.0000 114 58.0000
28 DrugI Phase1 Female 36-45 Rash 46.4816 214 55.0024
29 DrugJ Phase2 Male 46-60 Dizziness 78.0000 115 82.0000
30 DrugJ Phase2 Male 46-60 Dizziness 80.6996 215 86.6894
31 DrugK Phase3 Female 18-25 None 88.0000 116 89.0000
32 DrugK Phase3 Female 18-25 None 92.7943 216 90.2346
33 DrugL Phase1 Male 26-35 Fatigue 60.0000 117 72.0000
34 DrugL Phase1 Male 26-35 Fatigue 55.1299 217 75.3182
35 DrugM Phase2 Female 36-45 Dizziness 62.0000 118 77.0000
36 DrugM Phase2 Female 36-45 Dizziness 64.8396 218 75.5687
37 DrugN Phase3 Male 46-60 Headache 80.0000 119 85.0000
38 DrugN Phase3 Male 46-60 Headache 83.6183 219 84.1884
39 DrugO Phase1 Female 18-25 Rash 58.0000 120 68.0000
40 DrugO Phase1 Female 18-25 Rash 62.4931 220 70.4536


PRACTICE AND COMMENT YOUR CODE: 

-->PLEASE FOLLOW OUR BLOG FOR MORE UPDATES.

TO FOLLOW OUR TELEGRAM CHANNEL CLICK HERE

Comments

Post a Comment